Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/232527CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS IMMUNOGENIC COMPOSITIONS
WO 26.11.2020
Int.Class C12N 15/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
Appl.No PCT/CA2019/051592 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
The present disclosure relates to DNA vaccines against Crimean-Congo Hemorrhagic Fever (CCHF) virus. The present disclosure also relates to CCHF virus sequences and their use for vaccination such as DNA vaccination. The present disclosure more particularly relates to artificial nucleic acid molecules that are able to encode a CCHF polypeptide of an infectious CCHF virus, a fragment or a variant thereof. The nucleic acid molecules of the present application are formulated as immunogenic compositions.
2.WO/2020/234547NOVEL BACTERIOPHAGE STRAINS AND USES THEREOF
WO 26.11.2020
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/FR2020/050848 Applicant VETOPHAGE Inventor CHATAIN-LY, Mai Huong
The present invention relates to a composition comprising a bacteriophage strain or a mixture of bacteriophage strains selected from strains such as those stored at the CNCM under numbers CNCM I-5409, CNCM I-5410, CNCM I-5491 and CNCM I-5492. The invention also relates to the therapeutic use of said strains in humans and animals to treat S. aureus infections, in particular for treating mastitis in animals.
3.WO/2020/236925MAMMALIAN CELL FOR PRODUCING MODIFIED VACCINIA ANKARA (MVA) VIRUS
WO 26.11.2020
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/US2020/033788 Applicant THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES Inventor MOSS, Bernard
The present invention relates to modified animal cells comprising a vaccinia virus gene encoding a protein having the activity of a vaccinia virus C12, C16, or C17 protein, and/or that is deficient in an activity that inhibits replication of MVA virus, such as ZAP activity. Also provided are altered MVA viruses that encode a protein comprising the activity of vaccinia virus C12 protein, a vaccinia virus C16 protein, or a vaccinia virus C17 protein, or that comprise a mutation in an MVA ORF encoding a decapping protein, such as ORF D9 or D10. Such viruses have an extended host range (i.e., (HRE MVA viruses). Also provided are methods of producing modified cells and HRE MVA viruses of the disclosure, as well as methods of producing progeny MVA virus in modified and unmodified animal cells. Also provided are methods of using MVA viruses of the disclosure to vaccinate individuals.
4.WO/2020/235543NUCLEIC ACID MOLECULE USED FOR PRODUCTION OF RECOMBINANT AAV VIRION
WO 26.11.2020
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Appl.No PCT/JP2020/019724 Applicant JCR PHARMACEUTICALS CO., LTD. Inventor GALINA I. GOLOVINA
The purpose of the present invention is to provide a method for increased efficiency in production of recombinant AAV particles. This nucleic acid molecule includes: (a) a base sequence coding for Rep protein of AAV or a functional equivalent thereof; (b) a base sequence coding for Cap protein of AAV or a functional equivalent thereof; (c) a base sequence including a first AAV inverse terminal repetition (ITR) or a functional equivalent thereof; (d) a base sequence including a second AAV inverse terminal repetition (ITR) or a functional equivalent thereof; (e) a base sequence, located between the first ITR and the second ITR, for inserting a base sequence coding for a foreign protein, and/or a base sequence coding for a foreign protein; (f) a base sequence including an adenovirus E2A region or a functional equivalent thereof; (g) a base sequence including an adenovirus E4 region or a functional equivalent thereof; and (h) a base sequence including an adenovirus VA1 RNA region or a functional equivalent thereof.
5.WO/2020/233102PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TUMOR OR CANCER, AND APPLICATION THEREOF
WO 26.11.2020
Int.Class A61K 35/766
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
766Rhabdovirus, e.g. vesicular stomatitis virus
Appl.No PCT/CN2019/123567 Applicant HANGZHOU EVERBRIGHT BIOLOGICS, LTD. Inventor QIN, Xiaofeng
Provided are a pharmaceutical composition for treatment of a tumor or cancer, and an application thereof. The pharmaceutical composition comprises an oncolytic rhabdovirus and a CD38 small molecule inhibitor such as rhein by means of direct local injection or systemic administration or intratumoral delivery. The oncolytic rhabdovirus has the property of recognizing tumor cells and would not cause damage to normal cells; moreover, the CD38 small molecule inhibitor can specifically inhibit the activity of T-cell receptor molecules; the use of the oncolytic rhabdovirus and the CD38 small molecule inhibitor in combination has significant advantages in safety and efficacy.
6.WO/2020/236811DRUG-RESISTANT INFLUENZA VIRUS STRAINS
WO 26.11.2020
Int.Class A61P 31/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
Appl.No PCT/US2020/033590 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor INGBER, Donald, E.
This disclosure provides immunogenic compositions and methods of producing immunogenic compositions sufficient to produce an antigen-specific immune response against variant influenza virus strains. Also provided herein are methods of identifying drug-resistant influenza virus strains.
7.WO/2020/234810MODIFIED ENVELOPE GLYCOPROTEINS FOR RETROVIRIDAE VIRAL VECTOR PSEUDOTYPING AND PROCESS FOR OBTAINING IT
WO 26.11.2020
Int.Class C07K 14/15
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
Appl.No PCT/IB2020/054804 Applicant INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA (IBET) Inventor ANTUNES TOMÁS, Hélio
The present invention describes the development of a modified envelope glycoproteins to pseudo-type viruses of the retroviridae family. These are derived from Murine leukaemiavirus amphotropic, Gibbon Ape leukaemia virus and feline endogenous virus envelopes. The improved envelope glycoproteins contain, among other modifications, newly introduced alternative cleavable sequences. The viral vectors pseudo-typed with these modified envelopes may be suitably employed for cargo delivery such as in gene and cell therapy applications, for the ex vivo and in vivo delivery of gene(s), protein(s), or molecule(s) of interest to a variety of target cells.
8.WO/2020/234428PHAGE AND TRANSDUCTION PARTICLES
WO 26.11.2020
Int.Class C12N 7/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
02Recovery or purification
Appl.No PCT/EP2020/064225 Applicant SNIPR BIOME APS. Inventor KRAUSE HAABER, Jakob
The invention relates to the production of phage and transduction particles using DNAs (eg, plasmids and helper phage, mobile genetic elements (MGEs) or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these. The particles are particularly useful for delivering toxic payloads into target bacteria for antibacterial action. Embodiments enable production of highly pure compositions of such particles for medical or environmental use and for containment of the particles, which may be useful for containing antibacterial action.
9.20200360497COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS
US 19.11.2020
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No 16942058 Applicant PrimeVax Immuno-Oncology, Inc. Inventor Bruce W. Lyday

Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and/or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.

10.20200360507INFLUENZA VACCINE
US 19.11.2020
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
Appl.No 16722437 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor Emmanuel Jules HANON

The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.